Company: EDSA
Filing Date: 2025-02-14
Form Type: 10-Q
Source: 0001171843-25-000866
Chunk: 49

Company: Edesa Biotech, Inc.
Filing Date: 2025-02-14
Form: 10-Q
Item: Part I, Item 1
Chunk 49
---
 2024

			383,040

			$
			24.93

			$
			18.33

			Three Months Ended December 31, 2023

			Balance - September 30, 2023

			420,615

			$
			25.60

			$
			18.84

			Granted

			500

			4.10

			3.10

			Expired

			(106
			)

			960.00

			960

			Balance - December 31, 2023

			421,009

			$
			25.46

			$
			18.67

During the three months ended December 31 2024, there were no employee or director options granted. During the three months ended December 31, 2023, there were 500 employee options granted and no director options granted. The options have a term of 10 years and an exercise price equal to the Nasdaq closing price on the grant date.

The weighted average contractual life remaining on the outstanding options at December 31, 2024 is 77 months.

The following table summarizes information about the options under the 2019 Plan outstanding and exercisable at December 31, 2024:

			Number of Options (#) 

			Exercisable at
			December 31, 2024 (#) 

			Range of Exercise Prices 

			Expiry Dates

			374

			374

			$
			246.96

			March 2025

			37,719

			37,719

			C$
			15.12

			August 2027 - Dec 2028

			43,031

			43,031

			$
			22.12

			Feb 2030

			51,006

			51,006

			$
			52.08 - 56.49

			September 2030 - Oct 2030

			81,041

			81,041

			$
			36.75 - 40.18

			March 2025 - Sep 2031

			58,753

			57,304

			$
			25.97

			March 2025 - Feb 2032